^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa (clinicaltrials.gov)
    P2, N=23, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed
    Trial completion
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide
    1d
    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov)
    P3, N=177, Active, not recruiting, University of Arkansas | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • bortezomib • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • thalidomide • melphalan
    1d
    Current treatment strategies for first relapse of high-risk neuroblastoma. (PubMed, Eur J Cancer)
    The most promising salvage options for patients responding insufficiently to treatment are the chemotherapy combinations, topotecan/vincristine/doxorubicin (TVD), topotecan/cyclophosphamide/etoposide (TCE), ifosfamide/carboplatin/etoposide (ICE) or topotecan/cyclophosphamide (TopoCy), or [131I]-mIBG therapy. Early-phase clinical trials are also a possible option in this setting.
    Review • Journal • IO biomarker
    |
    MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification
    |
    carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan
    1d
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    1d
    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA) (clinicaltrials.gov)
    P3, N=90, Recruiting, Sinocelltech Ltd.
    New P3 trial
    |
    bortezomib • cyclophosphamide
    1d
    A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    cyclophosphamide • decitabine • Proleukin (aldesleukin)
    1d
    B7-H3.CD28Z.CART in CNS Neoplasms (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Robbie Majzner
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV
    2d
    DSN1 drives breast cancer progression via cell cycle regulation: diagnostic and therapeutic implications. (PubMed, Front Oncol)
    Drug sensitivity analysis showed that the DSN1 high expression group was resistant to drugs such as Epirubicin, Cyclophosphamide, Ribociclib, and Palbociclib, but relatively sensitive to tamoxifen and lapatinib. DSN1 contributes to breast cancer progression by modulating cell cycle pathways, making it a potential diagnostic and therapeutic target with clinical applicability.
    Journal
    |
    CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6) • CCNB1 (Cyclin B1)
    |
    Ibrance (palbociclib) • lapatinib • tamoxifen • cyclophosphamide • Kisqali (ribociclib) • epirubicin
    2d
    LS1781: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (clinicaltrials.gov)
    P2, N=80, Recruiting, Mayo Clinic | Trial completion date: Mar 2026 --> Nov 2033 | Trial primary completion date: Dec 2025 --> Feb 2031
    Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • DNMT3A (DNA methyltransferase 1) • SF3B1 (Splicing Factor 3b Subunit 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • SRSF2 (Serine and arginine rich splicing factor 2) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • CD4 (CD4 Molecule) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    IDH2 mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • Truxima (rituximab-abbs) • Hemady (dexamethasone tablets) • Mabtas (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • dexamethasone injection
    2d
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide
    3d
    Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) (clinicaltrials.gov)
    P2, N=111, Recruiting, First Affiliated Hospital of Zhejiang University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 positive • HR positive
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Herceptin (trastuzumab) • paclitaxel • Loqtorzi (toripalimab-tpzi) • cyclophosphamide • epirubicin • trastuzumab rezetecan (SHR-A1811)
    3d
    GMMG-HD7: Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7) (clinicaltrials.gov)
    P3, N=662, Active, not recruiting, University of Heidelberg Medical Center | Trial completion date: Mar 2027 --> Jun 2028 | Trial primary completion date: May 2025 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    lenalidomide • bortezomib • doxorubicin hydrochloride • cyclophosphamide • dexamethasone • Sarclisa (isatuximab-irfc) • dexamethasone injection